Harvard Bioscience to attend Benchmark’s 9th Annual Discovery One-on-One Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Harvard Bioscience (Nasdaq: HBIO) will participate in The Benchmark Company’s 9th Annual Discovery One-on-One Conference on November 18, 2020. CEO Jim Green and CFO Michael Rossi will engage in virtual meetings throughout the day. Interested investors can schedule a meeting by contacting their Benchmark representative or directly reaching out to Vince Curatola. Presentation materials will be available on the company’s investor relations page that same day at 8:00 AM ET. Harvard Bioscience specializes in technologies for drug development and serves a wide range of global customers.
Details
News Market Reaction – HBIO
The recorded move for HBIO in the trading session of this news was -1.48%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLLISTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), today announced that Jim Green, Chairman, President and CEO, and Michael Rossi, CFO will participate in The Benchmark Company’s 9th Annual Discovery One-on-One Conference. The virtual event will take place on Wednesday, November 18, 2020 with virtual investor meetings held throughout the day.
To schedule a meeting with management, please contact your Benchmark Company representative or Vince Curatola at vcuratola@benchmarkcompany.com or nyc@clearthink.capital.
A copy of the materials to be presented at the conference will be available on the investor relations page of the Harvard Bioscience website on November 18, 2020 at 8:00 AM ET.
About Harvard Bioscience
Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Our customers range from renowned academic institutions and government laboratories, to the world’s leading pharmaceutical, biotechnology and clinical research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
For investor inquiries, please contact Michael A. Rossi, Chief Financial Officer at (508) 893-8999.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.